MX2020002622A - Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida. - Google Patents

Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.

Info

Publication number
MX2020002622A
MX2020002622A MX2020002622A MX2020002622A MX2020002622A MX 2020002622 A MX2020002622 A MX 2020002622A MX 2020002622 A MX2020002622 A MX 2020002622A MX 2020002622 A MX2020002622 A MX 2020002622A MX 2020002622 A MX2020002622 A MX 2020002622A
Authority
MX
Mexico
Prior art keywords
benzylacetamide
morpholinoethoxy
pyridin
phenyl
solid forms
Prior art date
Application number
MX2020002622A
Other languages
English (en)
Spanish (es)
Inventor
Michael P Smolinski
Original Assignee
Athenex Hk Innovative Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65517772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020002622(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Athenex Hk Innovative Ltd filed Critical Athenex Hk Innovative Ltd
Publication of MX2020002622A publication Critical patent/MX2020002622A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2020002622A 2017-09-07 2018-09-07 Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida. MX2020002622A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555390P 2017-09-07 2017-09-07
PCT/US2018/049829 WO2019051147A1 (en) 2017-09-07 2018-09-07 SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDIN-2-YL) -N-BENZYLACETAMIDE

Publications (1)

Publication Number Publication Date
MX2020002622A true MX2020002622A (es) 2020-10-01

Family

ID=65517772

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002622A MX2020002622A (es) 2017-09-07 2018-09-07 Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.
MX2023001805A MX2023001805A (es) 2017-09-07 2020-03-06 Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023001805A MX2023001805A (es) 2017-09-07 2020-03-06 Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.

Country Status (24)

Country Link
US (4) US10669236B2 (enExample)
EP (2) EP4674486A3 (enExample)
JP (3) JP7843116B2 (enExample)
KR (2) KR102691700B1 (enExample)
CN (2) CN111278808B (enExample)
AU (2) AU2018330163B2 (enExample)
BR (1) BR112020004419A2 (enExample)
CA (1) CA3074831A1 (enExample)
DK (1) DK3679016T3 (enExample)
ES (1) ES3056703T3 (enExample)
FI (1) FI3679016T3 (enExample)
HR (1) HRP20260002T1 (enExample)
IL (2) IL326637A (enExample)
LT (1) LT3679016T (enExample)
MX (2) MX2020002622A (enExample)
PL (1) PL3679016T3 (enExample)
PT (1) PT3679016T (enExample)
RS (1) RS67706B1 (enExample)
SG (1) SG11202001868RA (enExample)
SI (1) SI3679016T1 (enExample)
SM (1) SMT202500467T1 (enExample)
TW (1) TWI815820B (enExample)
WO (1) WO2019051147A1 (enExample)
ZA (1) ZA202106139B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP4186890A1 (en) 2021-11-29 2023-05-31 Moehs Ibérica, S.L. Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin
CN115010655A (zh) * 2022-07-21 2022-09-06 重庆迈德凯医药有限公司 一种替尼布林的纯化方法
WO2026022219A1 (en) 2024-07-24 2026-01-29 Almirall, S.A. Injectable formulations comprising tirbanibulin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
DE60209704T2 (de) * 2001-05-22 2006-11-16 Pfizer Products Inc., Groton Neue kristallforme von azithromycin
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
PL1836169T3 (pl) 2004-12-28 2012-07-31 Kinex Pharmaceuticals Llc Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
DE602006019822D1 (de) * 2005-09-13 2011-03-10 Sicor Inc Reines rocuroniumbromid
ES2500165T3 (es) * 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
KR20090064400A (ko) * 2006-09-28 2009-06-18 머크 앤드 캄파니 인코포레이티드 Ｈｄａｃ 억제제 및 킬레이트화 가능한 금속 화합물 및 금속-ｈｄａｃ 억제제 킬레이트 착물의 약제학적 조성물
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) * 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
EP2160394A1 (en) * 2007-05-22 2010-03-10 Ultimorphix Technologies B.v. Tenofovir disoproxil hemi-fumaric acid co-crystal
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用
SI3592355T1 (sl) 2017-03-10 2026-04-30 Atnx Spv, Llc KX2-391/KX-01 za uporabo pri zdravljenju aktinične keratoze

Also Published As

Publication number Publication date
US20220098152A1 (en) 2022-03-31
BR112020004419A2 (pt) 2020-09-08
SMT202500467T1 (it) 2026-03-09
RU2020112539A3 (enExample) 2022-04-19
DK3679016T3 (da) 2025-12-15
KR20200081359A (ko) 2020-07-07
US12215083B2 (en) 2025-02-04
AU2023201010A1 (en) 2023-03-23
AU2018330163A1 (en) 2020-03-26
HRP20260002T1 (hr) 2026-02-27
CN111278808A (zh) 2020-06-12
TW201920160A (zh) 2019-06-01
MX2023001805A (es) 2023-03-13
AU2018330163B2 (en) 2023-02-02
KR102691700B1 (ko) 2024-08-02
IL272992A (en) 2020-04-30
CA3074831A1 (en) 2019-03-14
AU2023201010B2 (en) 2024-10-03
CN111278808B (zh) 2024-04-26
CN118439992A (zh) 2024-08-06
KR20240119192A (ko) 2024-08-06
JP2025131661A (ja) 2025-09-09
JP7843116B2 (ja) 2026-04-09
EP4674486A3 (en) 2026-03-25
LT3679016T (lt) 2026-02-10
SG11202001868RA (en) 2020-03-30
EP4674486A2 (en) 2026-01-07
RS67706B1 (sr) 2026-02-27
FI3679016T3 (fi) 2025-12-12
SI3679016T1 (sl) 2026-04-30
EP3679016A1 (en) 2020-07-15
US20200255380A1 (en) 2020-08-13
US20250115555A1 (en) 2025-04-10
ZA202106139B (en) 2026-04-29
RU2020112539A (ru) 2021-10-08
PL3679016T3 (pl) 2026-03-02
PT3679016T (pt) 2025-12-05
JP2020533412A (ja) 2020-11-19
US20190071402A1 (en) 2019-03-07
TWI815820B (zh) 2023-09-21
US10669236B2 (en) 2020-06-02
IL326637A (en) 2026-04-01
ES3056703T3 (en) 2026-02-24
US11230527B2 (en) 2022-01-25
WO2019051147A1 (en) 2019-03-14
JP2023157909A (ja) 2023-10-26
EP3679016A4 (en) 2021-09-29
EP3679016B1 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
IL288104A (en) Heterocyclic compounds, preparation methods and uses thereof
GT201700136A (es) Formas sólidas de un inhibidor ask 1
CL2019003144A1 (es) Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
ECSP17030878A (es) Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
MX374788B (es) Anticuerpos anti-tim3 y metodos de uso.
MX386587B (es) ANTICUERPOS ANTI-CD79b Y MÉTODOS DE USO.
MX2019003406A (es) Estructuras de nonofibra y metodos de uso de las mismas.
CR20190271A (es) Anticuerpos antitau y métodos de uso
MX372675B (es) Anticuerpos anti-jagged1 y metodos de uso.
MX372658B (es) Anticuerpos anti-cd3 y metodos de uso.
DK3962601T3 (da) 5-HT2A-agonister til anvendelse til behandling af depression
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
MX2022002954A (es) Anticuerpos anti-htra1 y metodos de uso de los mismos.
IL280809B (en) Novel compositions, their use, and methods for their formation
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
DK3658547T3 (da) Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
CR20200089A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
CL2020002333A1 (es) Anticuerpos anti-klk5 y métodos de uso.
CL2021003498A1 (es) Compuesto de pirazolona y pirimidina, y método de preparación y uso del mismo
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
MX377774B (es) Formulaciones de proteinas.
EP3998254A4 (en) 2-AMINOPYRIMIDINE COMPOUND AND USE THEREOF
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
MX382864B (es) Formulaciones de anticuerpos cristalinos.
MX2023001805A (es) Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.